Herold Advisors’s BioNTech BNTX Stock Holding History

Herold Advisors’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-2,250	Closed	-$240K	–	256
2025 Q2	$240K	Hold	2,250	–	–	0.05%	270
2025 Q1	$205K	Hold	2,250	–	–	0.05%	263
2024 Q4	$256K	Hold	2,250	–	–	0.06%	238
2024 Q3	$267K	Buy	+2,250	New	+$207K	0.06%	234
2024 Q2	–	Sell	-2,200	Closed	-$203K	–	266
2024 Q1	$203K	Buy	2,200 +150	+7%	+$14.4K	0.05%	255
2023 Q4	$216K	Buy	2,050 +50	+3%	+$5.04K	0.06%	229
2023 Q3	$217K	Sell	2,000 -1,000	-33%	-$111K	0.07%	227
2023 Q2	$324K	Hold	3,000	–	–	0.1%	191
2023 Q1	$374K	Hold	3,000	–	–	0.13%	163
2022 Q4	$451K	Hold	3,000	–	–	0.19%	126
2022 Q3	$404K	Hold	3,000	–	–	0.19%	124
2022 Q2	$447K	Hold	3,000	–	–	0.2%	124
2022 Q1	$512K	Buy	3,000 +1,000	+50%	+$168K	0.18%	125
2021 Q4	$515K	Hold	2,000	–	–	0.2%	123
2021 Q3	$545K	Buy	+2,000	New	+$636K	0.21%	118

Other funds holding BNTX

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Herold Advisors's BNTX Position: Q3 2025 in Review

Herold Advisors sold out of BioNTech (BNTX) in Q3 2025, closing a stake of 2,250 shares — an estimated $240K sold.

Herold Advisors first reported a position in BNTX in Q3 2021 and held it in 15 quarters. The position peaked at $545K in Q3 2021. 254 funds tracked by Wall St. Rank hold BNTX as of Q3 2025.

Herold Advisors reported no remaining BioNTech position as of Q3 2025 after selling out during the quarter.
Herold Advisors sold 2,250 BioNTech shares in Q3 2025, an estimated $240K.
Herold Advisors first reported a position in BioNTech in Q3 2021 and held it in 15 quarters.
Herold Advisors's BioNTech position peaked at $545K in Q3 2021.
254 funds tracked by Wall St. Rank held BioNTech as of Q3 2025.

Based on Herold Advisors's 13F filing for Q3 2025, filed 13 Nov 2025.